Beneficial vs harmful effects of pharmacological treatment of patent ductus arteriosus: A Bayesian meta-analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Randomized controlled trials (RCTs) have failed to demonstrate beneficial effects of the pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. We conducted a Bayesian model averaged (BMA) meta-analysis of RCTs comparing pharmacological treatment of PDA with placebo or expectant treatment.
Methods
We searched for RCTs including infants with gestational age (GA) ≤32 weeks and with a rate of open-label treatment of less than 25% in the control arm. Primary outcome was mortality and secondary outcomes included bronchopulmonary dysplasia (BPD). We calculated Bayes factors (BFs). The BF +/- is the ratio of the probability of the data under H + (pharmacological treatment is beneficial) over the probability of the data under H - (pharmacological treatment is harmful).
Results
Five RCTs were included (1341 infants). BMA showed strong evidence in favor of a harmful effect of medication for BPD (BF +/- =0.02) and BPD or death (BF +/- =0.03). When the two largest trials, which used early (<72 h) ibuprofen in infants with GA ≤28 weeks, were pooled, the BMA demonstrated moderate evidence in favor of higher mortality in the medication group (BF +/- =0.24).
Conclusions
Early ibuprofen treatment of a PDA in extremely preterm infants may result in more complications than clinical benefit.
